

ASX Announcement 5 December 2019

Elixinol's Comments on Potential Class Action

Elixinol Global Limited (Elixinol Global or the Company) (ASX:EXL; OTCQX:ELLXF), wishes to provide an update regarding Elixinol, LLC, a Colorado Limited Liability Company (EXU).

On 5 December 2019 [Australian Eastern Standard Time], Elixinol Global became aware of a yet-tobe served class-action suit having been filed in the United States District Court for the Northern District of California that alleges, amongst other allegations, that EXU's products are mislabeled as dietary supplements and that this may constitute misleading conduct. Elixinol Global believes that its products are accurately labeled and that the claims are without merit. Elixinol Global intends to defend itself against any such suits.

Furthermore, Elixinol Global believes this class-action suit is part of an industry-wide approach by the same class of plaintiffs based on reports that hemp-derived CBD brands Charlotte's Web (listed on Toronto Stock Exchange) and the Infinite Products Co have also been advised of proposed class action lawsuits filed in California in respect of the same subject matter as the claim against EXU.

This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Teresa Cleary General Counsel & Company Secretary

teresa.cleary@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products.

Elixinol Global's businesses include:

 Elixinol LLC (Elixinol), a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;



- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products; and
- Nunyara Pharma Pty Ltd (Nunyara), founded in 2014 to participate in the emerging Australian medicinal cannabis market. Nunyara holds a manufacturing licence and its application for cultivation to the Office of Drug Control is currently pending approval.

See more at www.elixinolglobal.com